Reply to Dr. Capovilla on “Reply to the article “Management of status epilepticus in adults. Position paper of the Italian League Against Epilepsy””
Publication date: Available online 6 April 2020Source: Epilepsy &BehaviorAuthor(s): Fabio Minicucci, Monica Ferlisi, Francesco Brigo, Oriano Mecarelli, Stefano Meletti, Umberto Aguglia, Roberto Michelucci, Massimo Mastrangelo, Nicola Specchio, Stefano Sartori, Paolo Tinuper
Publication date: Available online 29 May 2020Source: SeizureAuthor(s): Monika Mochol, Erik Taubøll, Pål Aukrust, Thor Ueland, Ole A. Andreassen, Sigrid Svalheim
Publication date: September 2020Source: Epilepsy &Behavior, Volume 110Author(s): Isabelle Sylvén, Ingrid Olsson, Tove Hallböök, Bertil Rydenhag, Colin Reilly
Publication date: September 2020Source: Epilepsy &Behavior, Volume 110Author(s): Yan Jiang, Yi Yang, Fei Feng, Ying Zhang, Xiao-Hang Wang, Fei-Lin Ni, Qun Hou, Li-Ping Zhang
Publication date: Available online 30 May 2020Source: Epilepsy &BehaviorAuthor(s): Naoto Kuroda
CONCLUSION: Almost all patients' clinical features were associated with 18q- syndrome. There are very few reported cases with similar genotype possibly caused by a de novo unequal recombination mechanism. PMID: 32468472 [PubMed - in process]
Publication date: September 2020Source: Epilepsy &Behavior, Volume 110Author(s): Christopher Ll Morgan, Stefan Varga, Wan Tsong, Sara Jenkins-Jones, Sarah Holden
The recent study by Vollono and colleagues  provides a concise report on a SARS-CoV-2 associated focal status epilepticus case. The authors hypothesize that a neurotropic mechanism may be involved in the development of the clinical presentation, albeit without PCR -proven neuroinvasion.
Conditions: Resistant Epilepsy, Drug; Adolescent Epilepsy; Children Epilepsy; Children and Adolescents With Resistant Epilepsies Interventions: Drug: MGCND00EP1; Drug: Placebo; Diagnostic Test: ECG; Diagnostic Test: EEG; Diagnostic Test: Blood and urine collection Sponsor: MGC Pharmaceuticals d.o.o Not yet recruiting
To report progress, to identify gaps, and to plan epilepsy surveillance and research activities more effectively, the Centers for Disease Control and Prevention (CDC) Epilepsy Program has summarized findings from selected CDC-supported surveillance and epi...
Abstract SUMMARYTaenia solium neurocysticercosis (NCC) is endemic in most of the world and contributes significantly to the burden of epilepsy and other neurological morbidity. Also present in developed countries because of immigration and travel, NCC is one of few diseases targeted for eradication. This paper reviews all aspects of its life cycle (taeniasis, porcine cysticercosis, human cysticercosis), with a focus on recent advances in its diagnosis, management, and control. Diagnosis of taeniasis is limited by poor availability of immunological or molecular assays. Diagnosis of NCC rests on neuroimaging finding...